About US
Contact us
-
Pharma raises prices to ring in 2019. Will it trigger action in Washington?It’s a new year, and many top pharma companies are taking the opportunity to raise prices for their big sellers. As the industry has in the past, several drugmakers opted to raise prices to ring in 202019/1/4
-
Pfizer, Merck shares smoking hot in 2018 despite doldrums for overall biopharma sectorBy the end of the last full week of 2018, the two best performers on the Dow Jones Industrial Average for the year were Pfizer and Merck & Co., up 22% and 38% respectively. The two pharma bigwigs2019/1/3
-
French inspectors find issues at Indian plant cited earlier by ItalyFrench inspectors found a lot they didn’t like about an Indian manufacturer when they inspected its operation for consideration of approving its ambroxol hydrochloride API. The problems led the Europe2019/1/3
-
FiercePharmaAsia—Possible Sun probe; Huahai warning letter; Eisai-UCL neuro pactThe possibility of a government investigation looms ever larger for Sun Pharma, as Indian regulators said they're indeed reviewing whistleblower allegations against the company. In a newly posted warn2019/1/2
-
Whistleblower complaint against Sun Pharma confirmed by Indian regulators: reportSun Pharma drew more unwanted attention this weekwhen India’s stock regulators confirmed they are examining whistleblower allegations against the company. “We have received the complaint against Sun2019/1/2
-
The valsartan carcinogen mess taught pharma a surprise manufacturing lesson. Will 2019 bring more?Industry wisdom is that there is nothing new to learn about tablet making. Drugmakers have been doing it essentiallythe same way for more than 100 years. But that idiom was turned on its head this yea2018/12/25
-
Gilead and Agenus sign cancer drug development dealGilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of up to five immuno-oncology (I-O) treatments. Under the terms of the deal, Gilead2018/12/24
-
Irish authorities demand €1.6bn in back tax from PerrigoThe Irish tax authority Revenue Commissioners has issued a Notice of Amended Assessment (NoA) to Perrigo stating the company owes €1.64bn in tax from 2013 intellectual property sales by Elan Pharma, w2018/12/24
-
As immuno-oncology heads into 2019, one thing is clear: It’s good to be MerckWhen 2018 began, there was still plenty of uncertainty surrounding the previously untreated lung cancer market—the holy grail for immuno-oncology drugmakers, thanks to its sheer size. Merck had the l2018/12/21
-
Talc lawyer says J&J's multibillion-dollar stock woes make settling look like a better dealWhat's bad for Johnson & Johnson shares is good for the trial lawyer leading the charge in the talc liability litigation—or so the lawyer says, as J&J scrambles to contain the damage from a bo2018/12/21